Loading
A phase 1/2 trial of EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide in mesothelioma, run by Beijing Biotech, now recruiting.
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma is a phase 1/2 interventional study registered as NCT07510815 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide. Conditions listed: Malignant Pleural Mesotheliomas. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Peritoneal mesothelioma, Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/